

10 Oct 2021 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: will a new oral antiviral be transformative for COVID?; OX40 drugs gain prominence in atopic dermatitis; J&J adds pace to RSV vaccine race; Sarepta leapfrogs Pfizer in DMD gene therapy; and how real-world evidence and randomized trials might go together.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 8 October 2021, including: will a new oral antiviral be transformative for COVID?; OX40 drugs gain prominence in atopic dermatitis; [Johnson & Johnson](#) adds pace to RSV vaccine race; [Sarepta Therapeutics, Inc.](#) leapfrogs [Pfizer Inc.](#) in DMD gene therapy; and how real-world evidence and randomized trials might go together.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Merck's Oral Antiviral Data In COVID-19 May Change Pandemic Outlook](#)" - Scrip, 1 Oct, 2021.)

(Also see "[Sanofi And Amgen Make The Case For OX40 Drugs In Atopic Dermatitis](#)" - Scrip, 4 Oct, 2021.)

(Also see "[J&J Sets The Pace In Race To \\$10bn RSV Vaccine Market](#)" - Scrip, 4 Oct, 2021.)

(Also see "[*Sarepta Leapfrogs Pfizer In The US, Launching DMD Gene Therapy Pivotal Trial*](#)" - Scrip, 4 Oct, 2021.)

(Also see "[*Janssen's Sarich: Randomized Controlled Trials, Real-World Evidence Go Best Together*](#)" - Scrip, 4 Oct, 2021.)

[Click here to explore this interactive content online](#) 